Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy

Authors :: Christopher R. Heery
Renee N. Donahue
Fatima Karzai
Peter A. Pinto
Marijo Bilusic
Houssein Abdul Sater
Beatriz Walter Rodriguez
William L. Dahut
Jenn Marte
Debrah Thompson
James L. Gulley
Guinevere Chun
Lisa M. Cordes
Mark Stern
Jeffrey Schlom
Ravi A. Madan
Source :: Journal of Clinical Oncology. 36:5083-5083
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 5083Background: PSA-TRICOM (Prostvac) is a vector-based vaccine designed to generate a robust immune response (IR) against PSA–expressing tumor cells. To date, studies of Prostvac in patients with ...

Subjects :: Cancer Research
business.industry
Prostatectomy
medicine.medical_treatment
urologic and male genital diseases
medicine.disease
Prostate cancer
Immune system
Oncology
Rilimogene Galvacirepvec/Rilimogene Glafolivec
Cancer research
Medicine
In patient
Vector (molecular biology)
business
Prostvac
Immune infiltrate

Full Text Access

Tools